SREBP-2, a new target of metformin?

BACKGROUND: Metformin, as the first-line treatment anti-diabetic drug, represents increasing evidence of a potential efficacy in improving dyslipidemia. However, the exact molecular mechanism(s) by which metformin influences lipid metabolism remains incompletely understood. METHODS: The HepG2 cells...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drug Des Devel Ther
Autori principali: Zhang, Fengxia, Sun, Wenxiu, Chen, Jianbo, Jiang, Lusheng, Yang, Ping, Huang, Yufang, Gong, Aihua, Liu, Shudong, Ma, Shizhan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287532/
https://ncbi.nlm.nih.gov/pubmed/30584280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S190094
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi